Improving clinical trials in the critically ill: Unique challenge-Sepsis

被引:35
作者
Annane, Djillali [1 ]
机构
[1] Univ Paris Sud, Univ Versailles SQY, Hop Raymond Poincare, AP HP,Serv Reanimat, Paris, France
关键词
sepsis; trial design; methodology; clinical trials; TUMOR-NECROSIS-FACTOR; INFLAMMATORY RESPONSE SYNDROME; SECRETORY PHOSPHOLIPASE A(2); RECEPTOR ANTAGONIST TRIAL; PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; SEPTIC SHOCK; PHASE-III; MONOCLONAL-ANTIBODY; SELECTIVE INHIBITOR;
D O I
10.1097/CCM.0b013e318192078b
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Objective: This article aimed at providing suggestions to improve the success rate of future sepsis trials. Design: Systematic review. Intervention: None. Measurements and main results: CENTRAL (The Cochrane Library Issue 2, 2007) was searched using "sepsis" OR "severe sepsis" OR "septic shock" as search terms. The search was restricted to studies designed and conducted in adults with severe sepsis or septic shock after June 1992, published before September 2007, and powered for survival analysis. Twenty-seven trials were included and analyzed. The author suggested six key points for the design and conduct of future sepsis trials: 1) avoid mixing patients with severe sepsis and septic shock; 2) restrict time window to less than 24 hrs from onset of the first organ dysfunction or shock; 3) include only undisputable sepsis; 4) use the Sepsis-related Organ Failure Assessment score for eligibility; 5) include a first interim analysis after enrollment of 25% of the planned sample size to check the actual basal risk of death and to recalculate the number of patients needed; 6) strictly control for concomitant treatments on the basis of the Surviving Sepsis Campaign. Conclusions: There is a need to limit the sources of heterogeneity in sepsis trials by a better definition of target populations, by a better estimation of basal risk of death, and by controlling cointerventions. (Crit Care Med 2009; 37[Suppl.]:S117-S128)
引用
收藏
页码:S117 / S128
页数:12
相关论文
共 39 条
  • [1] Abraham E, 1998, LANCET, V351, P929
  • [2] Efficacy and safety of LY315920Na/S-5920, a selective inhibitor of 14-kDa group IIA secretory phospholipase A2, in patients with suspected sepsis and organ failure
    Abraham, E
    Naum, C
    Bandi, V
    Gervich, D
    Lowry, SF
    Wunderink, R
    Schein, RM
    Macias, W
    Skerjanec, S
    Dmitrienko, A
    Farid, N
    Forgue, ST
    Jiang, F
    [J]. CRITICAL CARE MEDICINE, 2003, 31 (03) : 718 - 728
  • [3] Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis -: A randomized controlled trial
    Abraham, E
    Reinhart, K
    Opal, S
    Demeyer, I
    Doig, C
    Rodriguez, AL
    Beale, R
    Svoboda, P
    Laterre, PF
    Simon, S
    Light, B
    Spapen, H
    Stone, J
    Seibert, A
    Peckelsen, C
    De Deyne, C
    Postier, R
    Pettilä, V
    Sprung, CL
    Artigas, A
    Percell, SR
    Shu, V
    Zwingelstein, C
    Tobias, J
    Poole, L
    Stolzenbach, JC
    Creasey, AA
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (02): : 238 - 247
  • [4] Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death
    Abraham, E
    Laterre, P
    Garg, R
    Levy, H
    Talwar, D
    Trzaskoma, BL
    Francois, B
    Guy, JS
    Bruckmann, M
    Rea-Neto, A
    Rossaint, R
    Perrotin, D
    Sablotzki, A
    Arkins, N
    Utterback, BG
    Macias, WL
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (13) : 1332 - 1341
  • [5] p55 tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock - A randomized controlled multicenter trial
    Abraham, E
    Glauser, MP
    Butler, T
    Garbino, J
    Gelmont, D
    Laterre, PF
    Kudsk, K
    Bruining, HA
    Otto, C
    Tobin, E
    Zwingelstein, C
    Lesslauer, W
    Leighton, A
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (19): : 1531 - 1538
  • [6] Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: A randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients
    Abraham, E
    Laterre, PF
    Garbino, J
    Pingleton, S
    Butler, T
    Dugernier, T
    Margolis, B
    Kudsk, K
    Zimmerli, W
    Anderson, P
    Reynaert, M
    Lew, D
    Lesslauer, W
    Passe, S
    Cooper, P
    Burdeska, A
    Modi, M
    Leighton, A
    Salgo, M
    Van der Auwera, P
    [J]. CRITICAL CARE MEDICINE, 2001, 29 (03) : 503 - 510
  • [7] *AC RESP DISTR SYN, 2000, NEW ENGL J MED, V342, P1301, DOI DOI 10.1056/NEJM200005043421801
  • [8] Multicenter evaluation of a human monoclonal antibody to Enterobacteriaceae common antigen in patients with Gram-negative sepsis
    Albertson, TE
    Panacek, EA
    MacArthur, RD
    Johnson, SB
    Benjamin, E
    Matuschak, GM
    Zaloga, G
    Maki, D
    Silverstein, J
    Tobias, JK
    Haenftling, K
    Black, G
    Cowens, JW
    [J]. CRITICAL CARE MEDICINE, 2003, 31 (02) : 419 - 427
  • [9] Selenium in Intensive Care (SIC):: Results of a prospective. randomized, placebo-controlled, multiple-center study in patients with severe systemic inflammatory response syndrome, sepsis, and septic shock
    Angstwurm, Matthias W. A.
    Engelmann, Lothar
    Zimmermann, Thomas
    Lehmann, Christian
    Spes, Christoph H.
    Abel, Peter
    Strauss, Richard
    Meier-Hellmann, Andreas
    Insel, Rudolf
    Radke, Joachim
    Schuettler, Juergen
    Gaertner, Roland
    [J]. CRITICAL CARE MEDICINE, 2007, 35 (01) : 118 - 126
  • [10] E5 murine monoclonal antiendotoxin antibody in gram-negative sepsis - A randomized controlled trial
    Angus, DC
    Birmingham, MC
    Balk, RA
    Scannon, PJ
    Collins, D
    Kruse, JA
    Graham, DR
    Dedhia, HV
    Homann, S
    MacIntyre, N
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (13): : 1723 - 1730